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Abstract 
 
The recent advances in controlled delivery systems for protein 
pharmaceuticals such as microspheres, liposomes, pumps and 
implants, have provided a new avenue for delivery of vaccine 
antigens. Adjuvants aimed at increasing the immunogenicity of 
recombinant antigens remain a focus in vaccine development 
worldwide, there is currently considerable care for the development 
of chitosan microspheres as controlled release of vaccines, since the 
major disadvantage of several currently available vaccines is the 
need for repeated administration. Microspheres prepared from the 
biodegradable and biocompatible polymers, chitosan have been 
shown to be effective adjuvants for a number of antigens. This 
review mainly focuses on chitosan microspheres adjuvant as vaccine 
delivery systems by summarizing our and other research groups’ 
investigation on properties of microspheres formulation 
encapsulating several kinds of antigens. The results indicate that 
compared with commonly used PLA and PLGA, chitosan 
biomaterial has several potentials in vaccine delivery systems. 
Chitosan microspheres can control the rate of release of entrapped 
antigens and therefore, offer generation adjuvant to replace or 
complement existing aluminium salts for vaccine potential. The 
review mainly aims to promote the investigation of chitosan 
microspheres adjuvant for antigens for world wide researcher.   
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Introduction 
Immunization has arguably been the most 
important way of protection against a number of 
devastating viral and bacterial infections [1]. 
Vaccine research is often focused on the 
identification and application of novel antigens. 
The response to those antigens is routinely 
optimized by assessing a variety of delivery 
methods, including variation of the adjuvant 
used, the dose and number of infections and the 
route of delivery. The application of new delivery 
systems to vaccination may allow effective 
utilization of vaccine antigens that have 
previously not been able to induce adequate or 
appropriate responses as well as improving the 
responses to existing vaccines [2]. 
Aluminium phosphate and aluminium hydroxide, 
which are currently the approved adjuvant for 
human vaccination in US, are widely used 
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vaccine adjuvants for humans at present. 
However, the use of alum-type adjuvant for 
immunization has some disadvantages [3-7]. 
Although alum is efficient at increasing humoral 
immunity, cell mediated immunity appears to be 
only slightly affected. Moreover some viral 
antigens are poor immunogens in alum [4, 8]. 
Also, alum is an undesirable adjuvant since it 
stimulates local production of granulomas and 
induces inflammation [7]. Conventional alum-
type vaccines requires multiple recall injections 
(e.g. Diphtheria, pertussis, tetanus, hydrophobia 
and hepatitis B) at appropriately timed intervals 
in order to obtain long lasting and optimal 
immune response. Therefore, development of 
more efficient and safe adjuvant / vaccine 
delivery systems requiring single administration 
to obtain high and long lasting immune responses 
is of primary importance. A new generation of 
more effective adjuvants [9], including 
liposomes, muramyl peptide and ISCOMs 
(Immunostimulatory Compounds), have been 
proposed to replace alum. 
In recent years there have been various attempts 
to demonstrate new immunization strategies to 
induce higher level and larger duration of 
immune responses following parenteral and / or 
oral administration. One of the means used to 
improve immunologic response has been to 
provide prolonged antigen release [5]. Controlled 
drug delivery technology using biodegradable 
polymers as carriers represents on of the most 
rapidly advancing areas of science. Controlled 
delivery systems consisting of biodegradable 
microspheres can potentially delivery either the 
antigens or adjuvants to the desired location at 
predetermined rates and durations to generate an 
optimal immune response. The carrier may also 
protect the vaccine from degradation until it is 
released. Other potential advantages of the 
controlled delivery approach include reduced 
systemic side effects and the possibility of 
coencapsulating multiple antigenic epitopes or 
both antigen and adjuvant in a single carrier. 
Biodegradable polymers provide sustained 
release of the encapsulated antigen and degrade 
in the body to nontoxic, low-molecular-weight 
products that are easily eliminated [5, 10]. The 
microspheres vaccine delivery system based on 
biodegradable polylactide (PLA) and polylactide-
co-glycolide (PLGA) has been extensively 
investigated due to the many advantages of the 
controlled-release delivery system [3, 5, 10-17]. 
The PLA and PLGA are biodegradable and 
biocompatible polymers, which are 
nonimmunogenic and have a long history of safe 
use in humans as sutures and as controlled 
delivery systems [11, 18-20]. The choice of PLA 
and PLGA as the matrix for vaccine formulations 
is based on its long-term safety in humans, its 
biodegradability, and the commercial availability 
of a variety of polymers of different molecular 
weights and monomer ratios [21]. Nevertheless, 
PLA and PLGA have some drawbacks, resulting 
from their hydrophobic nature. The difference in 
physico-chemical properties between hydrophilic 
antigens and hydrophobic polymer matrix leads 
to a lower encapsulation efficiency within 
microspheres, and a higher burst effect of antigen 
release from microspheres. Furthermore, during 
the initial vaccine release phase in vivo, the 
hydrophobic PLA or PLGA prevents the 
penetration of water into the center of the 
microspheres, thus forming an acidic 
microenvironment due to the accumulated acidic 
breakdown products, such as lactic and glycolic 
acid end groups.    
Chitosan derived by the deacetylation of chitin, 
which is a polymer of D-glucosamine and N-
acetyl D-glucosamine. Chitosan is well known 
for its hydrophilic, biocompatible, biodegradable 
and non-toxic properties [22, 23]. Chitosan 
particle delivery system can reduce the clearance 
rate from the nasal cavity, there by increasing the 
contact time of the delivery system with the nasal 
mucosa [24]. Chitosan suspensions or micro and 
nanoparticles have been reported to have immune 
stimulating activity such as increasing 
accumulation and activation of macrophage and 
poly morphonuclear cell, promoting resistance to 
infections of microorganisms, and inducing 
cytokines [25].  
Although, the currently available vaccines 
represent an outstanding success story in modern 
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medicine and have had a dramatic effect on 
morbidity and mortality worldwide, it is clear that 
improvements are required in the current vaccine 
delivery technologies to control the conventional 
approaches [26].  
 
 
Figure 1. Structure of chitin and chitosan 
Emergence for New and Improved Vaccines 
 
Despite the success of vaccines, there is a clear 
need for the development of new vaccines against 
infectious diseases for which none are yet 
available, or are inadequate, including HIV, 
HCV, Neisseria Meningitidis type 3, 
Tuberculosis and Malaria. Unfortunately, these 
pathogens have proven exceptionally difficult to 
control using traditional approaches to vaccine 
development and novel approaches will be 
needed. Vaccines are also needed to protect 
against emerging or reemerging infectious 
diseases, including West Nile, SARS, Ebola, 
Hanta and Dengue viruses. In addition, improved 
vaccines are needed to protect against the thread 
of pandemic strains of influenza virus and the 
continued growth and speed of antimicrobial 
resistant organisms. In addition, vaccines may be 
required to protect against the threat of 
bioterrorism [27]. Moreover, there is an 
increasing awareness that infectious agents can 
cause chronic diseases, which might be prevented 
or treated with novel vaccines.     
Hence vaccines may also be considered as 
potential therapeutic agents to treat established 
infections. It is clear that novel vaccine delivery 
technologies will be required to enable the 
development of these new vaccines, particularly 
those designed as therapies against chronic 
infections or cancers. The safety profiles of 
therapeutic vaccines may look very difficult from 
traditional vaccines, which are used to protect 
against infection. Therapeutic vaccines, 
particularly if used in an oncology setting, or to 
treat established life-threatening infectious 
diseases, would most likely be able to sustain a 
higher level of adverse effects without damaging 
the marketability of the product.     
 
Examples of Alternate Approaches to Vaccine 
Delivery 
1) Antigen delivery system / Adjuvants: 
Alum, MF59, PLG, Liposomes, 
Virosomes, etc. 
2) Adjuvant delivery system: PLG, MF59, 
ISCOMS, etc. 
3) DNA vaccine delivery systems: PLG, 
Gene gun, Alpha viruses, etc. 
4) Nonreplicating viral vectors: Alpha 
viruses, etc. 
5) Live bacterial and viral vectors: 
Salmonella, Adenoviruses, etc. 
6) Intranasal vaccines: LT mutants and / or 
bioadhesive polymers etc. 
7) Oral vaccines: LT mutants, Enteric coated 
formulations, etc. 
8) Topical vaccines: Vaccine patches 
(Lomai) 
9) Micro needles: Onvax (Becton 
Dickinson), Macro flux (Alza), etc. 
10) Needle free devices: Epidermal powder 
immunization (Powderject), Bioreactor 
etc. 
Although the term vaccine “adjuvants” and 
“delivery systems” have often been used 
interchangeably, a clear distinction can often be 
made and the respective roles of each can be 
more clearly defined. Classically, adjuvants have 
been defined by what they do, which is to 
enhance the immune responses to antigens, rather 
than by how they achieve this. 
 
Chitosan Microspheres 
Characteristics of Chitosan 
Chitosan is a natural polysaccharide consisting of 
glucosamine and N-acetyl glucosamine. It can be 
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derived through the partial deacetylation of 
chitin, the major compound of exoskeletons in 
crustaceans. The term chitosan refers to a series 
of polymers with different molecular weights, 
viscosity, degrees of deacetylation, pKa, etc. The 
molecular unit of chitosan has one amino group 
and two hydroxyl groups that are potentially 
capable of reacting with an acidic medium. The 
amino group in chitosan has a pKa value of ~6.5; 
hence, chitosan is positively charged and is 
soluble in an acidic solution with a charge density 
that is dependent on the pH and the degree of 
deacetylation. The presence of an amino group in 
chitosan enables it to chemically react with 
anionic systems, thereby resulting in the 
modification of the physicochemical 
characteristics of such combinations [22]. In 
addition, the free amino group in chitosan is 
readily available and reacts with a number of 
negatively charged polymers. Chitosan is one of 
the most promising polymers because of its 
nontoxic, polycationic, biocompatible, and 
biodegradable nature, and particularly due to its 
mucoadhesive and permeation-enhancing 
properties.  
The strong mucoadhesive property of chitosan is 
most important for drug delivery through the 
mucosal routes. In addition, the interaction of the 
positively charged chitosan with the negatively 
charged mucin layer and the tight junctions 
facilitates the paracellular transport of 
hydrophilic macromolecules by opening the tight 
junctions of the mucosal barriers[28-31]. The 
strong mucoadhesive properties of chitosan point 
to its potential as a permeation enhancer for 
mucosal drug delivery. Nasal and oral drug 
delivery researches have confirmed that 
significantly higher amounts of macromolecules 
can be absorbed across the mucosal barrier after 
co-administration with chitosan [28, 32]. The 
absorption-enhancing effect of chitosan has been 
found to be due to the combination of improved   
mucoadhesion between the formulation and the 
nasal tissues and the transient effect of chitosan 
on the paracellular pathways. Dodane et al. 
demonstrated that chitosan has an effect in 
modifying paracellular transport [30]. There are 
several researches that show the efficacy of 
chitosan as an adjuvant and delivery system for 
mucosal vaccines. The Bordetella pertusis 
filamentous haemagglutinin and recombinant 
pertusis toxins have been shown to induce strong 
antigen-specific systemic and mucosal immune 
responses after IN administration with chitosan 
[33]. Diphtheria toxin nasally co-administrated 
with chitosan induced systemic and local immune 
responses [34]. In several researches, mucosal 
vaccination with chitosan induced cell-mediated 
immune responses as well as humoral immune 
responses.  
In a study conducted by Xie et al., the H. pylori 
vaccine with chitosan as an adjuvant via oral 
delivery induced both helper T cell 1 (Th1)- and 
helper T cell 2(Th2)-type immune responses [35]. 
The intranasally delivered chitosan-diphtheria 
vaccine in primed animals was found to induce a 
mixed Th1/Th2 response,which indicates the 
induction of both humoral and cellular immune 
responses [22]. Chitosan was also shown to have 
immune-stimulating activity, such as increasing 
the accumulation and activation of macrophages, 
promoting the production of cytokines, and 
enhancing cytotoxic T lymphocyte (CTL) 
responses [36]. The mucociliary clearance rate 
can be decreased by the use of mucoadhesive 
polymers. Several studies showed that chitosan 
prolonged the residence time of nasally delivered 
drugs at the absorption site [37]. 
 
Mucoadhesive microspheres 
Particulate carrier technology offers a valuable 
advance for use as vaccine delivery systems by 
the introduction of vaccines to the carriers such 
as  nano/microspheres, emulsions, liposomes, 
virosomes, immune stimulating complex 
(ISCOM), virus like particles (VLPs), etc. 
Microspheres which constitute a significant part 
of these particulate vaccine delivery systems have 
several useful attributes to stimulate host immune 
system. First, the most useful property of 
microspheres as vaccine delivery systems is to 
offer an optimum size for particle trafficking into 
the body as well as uptake by antigen presenting 
cells (APCs). It has been well documented that 
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the drug carrying microspheres with an 
appropriate size can be internalized by APCs 
thereby allowing for easy transport of the vaccine 
formulations across the cell membrane [38].  The 
sizes of microparticles were an important 
parameter influencing the efficacy to enhance 
immunogenicity, because small particles (<10 
μm) appeared to be more immunogenic than large 
ones (>10 μm) [39, 40]. A second valuable 
property of microspheres is to increase the 
residence time of vaccines at the mucosal surface 
compared to solutions. It has been reported that 
microspheres exert a direct effect on the nasal 
mucosa because the epithelial cells dehydrate 
causing the tight junction to separate by 
absorbing water from mucus and swelling [41]. 
The increased residence time of microspheres at 
the mucosal surface may facilitate the increased 
uptake of vaccine formulation incorporated with 
the microspheres by more increased contact time 
between the vaccine and the mucosal membrane.  
The microspheres with a mucoadhesive property 
can offer additional advantages that may help to 
prolong residence time and improve uptake of 
vaccines incorporated with them. Chowdary et al. 
well documented the advantages of 
mucoadhesive drug delivery systems such as 
bioavailability improvement of drugs, absorption 
enhancement of macromolecules and prolonged 
residence time at the site of application [42]. 
Chitosan among these mucoadhesive agents is the 
most widely used natural polymer for potential 
application of mucosal vaccine delivery. The 
chitosan microspheres as a delivery system for 
oral vaccination were evaluated in several 
studies. In a study conducted by Tian et al., fish 
immunized by oral vaccination with a plasmid 
DNA (pDNA) containing major capsid protein 
(MCP) gene of lymphocystis disease virus 
(LCDV) encapsulated in chitosan microspheres 
showed significantly enhanced systemic immune 
responses in comparison with fish vaccinated 
with naked pDNA [43]. The chitosan 
encapsulated tetanus toxoid (CS-TT) 
microparticles have been shown to induce antigen 
specific IgA in intestinal lavage, faeces, intestinal 
washings and strong antigen specific IgG in the 
systemic circulation after oral immunization [44]. 
Since chitosan polymers have already been used 
for a variety of biomedical purposes, including 
the preparation of controlled drug delivery 
systems, including proteins [45], it was an 
excellent choice for a vaccine delivery system. 
Microspheres represent an attractive approach to 
vaccine delivery since it has been shown on many 
occasions that microspheres are taken up 
efficiently by Antigen Presenting Cells (APC) in-
vitro (39) and in-vivo [40]. In addition, 
microspheres have also been shown to be taken 
up by APC, which then migrated to the T-cell 
area of local lymph nodes and differentiated in to 
Dentritic cells (DC) [39]. 
Compared with PLA and PLGA, Chitosan is a 
new cheap biomaterial and fewer reports are 
published on its use as a drug delivery carrier. In 
last 5 years, our research groups have focused on 
studying the preparation of chitosan microspheres 
as a suitable vaccine delivery system [46]. 
 
Conclusion 
Biodegradable chitosan microspheres are 
extremely flexible delivery systems capable of 
encapsulating a wide range of antigens. A single 
injection or oral administration of chitosan 
microspheres could provide a sustained, higher or 
equal antibody titer than an alum adsorbed 
vaccine. Furthermore, the chitosan polymer 
improves cellular immunity, a property which 
alum lacks. Therefore, chitosan polymer has 
potential use as a new adjuvant instead of alum, 
and, the microsphere formulation is very suitable 
to be as vaccine delivery system. Chitosan is a 
novel biomaterial, and it is very worth studying. 
 
 
References 
 
1. Plotkin SL, Plotkin SA, in: Plotkin SA, 
Mortimer EA Jr. (Eds). A short history of 
vaccination and vaccines, Saunders, 
Philadelphia, PA, 1988, 1-7. 
47 
 
Saravana et al. International Journal of Drug Delivery 3 (2011) 43-50 
 
2.  Shari Lofthouse.  Immunological aspects of 
controlled antigen delivery. Adv Drug Deli 
Rev 2002; 54:863-870. 
3. Men Y, Thomasin C, Merkle HP, Gander B, 
Corradin G.   A Single administration of 
tetanus toxin in biodegradable microspheres 
elicits T cell and antibody responses similar 
or superior to those obtained with aluminium 
hydroxide. Vaccine 1995; 13:683-689. 
4. Warren HS, Vogel FR, Chedid LA. Current 
status of immunological adjuvants. Ann Rev 
Immunol 1986;4: 369-376. 
5. Kohn J, Niemi SM, Albert EC, Murphy JC, 
Langer RS, Fox JG. Single-step 
immunization using a controlled release, 
biodegradable polymer with sustained 
adjuvant activity. J Immunol Methods 1986; 
95: 31- 37.   
6. Physician’s Desk Reference, 46th ed, Medical 
Economics Data. 1992; 1544-1546. 
7. Bittle JL, Murphy FL.  Vaccine Biotechnol. 
1989; 33: 313. 
8. Allison AC, Byars NE. Immunological 
adjuvants: desirable properties and side 
effects. Molec  Immunol 1991; 28: 279-283. 
9. Zhao Z, Leong KW. Controlled delivery of 
antigens and adjuvants in vaccine 
development. J Pharm Sci 1996; 85 (12): 
1261-1270. 
10. Nellore RV, Pande PG, Young D, Bhagat 
HR. Evaluation of biodegradable 
microspheres as vaccine adjuvant for 
Hepatitis B surface antigen. J Parenteral Sci 
Tech 1992;  46: 176-180. 
11. Yamaguchi K, Anderson JM. In vivo 
biocompatibility studies of medisorb 65/35 
D.L-lactide / glycolide copolymer 
microspheres. J Control Release 1993; 24: 81- 
86.  
12. Aguado MT, Lambert PH.  Controlled release 
vaccines biodegradable polylactide-
polyglycolide (PL / PG) microspheres as 
antigen vehicles. Immunobiol 1992;184: 113-
125. 
13. Esparza I, Kissel T. Parameters affecting the 
immunogenicity of microencapsulated tetanus 
toxoid. Vaccine 1992; 10: 714-720. 
14. Raghuvanshi RS, Singh M, Talwar GP. 
Biodegradable delivery system for single step 
immunization with tetanus toxoid. Int  J 
Pharm 1993; 93: R1-R5. 
15. Alonso MJ, Cohen S, Park TG, Gupta RK, 
Siber GR, Langer R. Determinants of release 
rate of tetanus vaccine from polyester 
microspheres. Pharm.Res 1993;10: 945-953. 
16. Alonso MJ, Gupta RK, Min C,  Siber GR,  
Langer R. Biodegradable microspheres as 
controlled-release tetanus toxoid delivery 
systems. Vaccine 1994; 12: 299-306. 
17. Change AC, Gupta RK. Stabilization of 
tetanus toxoid in poly (D,L,lactide-co-
glycolic acid) microspheres for the controlled 
release of antigen. J Pharm Sci 1996; 85: 129-
132. 
18. Langer R. New methods of drug delivery. 
Science 1990; 249: 1527-1533. 
19. Tice TR, Mason DW, Ghley RM. Clinical use 
and future of parenteral microspheres delivery 
systems, in: F.Prescot, W.S.Nimmo (Eds.), 
Drug Delivery and its Therapeutic 
Applications, Wiley, London, 1989, Chapter 
21. 
20. Wise DL, Fellman TD, Sanderson JE, 
Wentworth RL. Lactide / glycolide polymers 
used in as surgical suture material, raw 
material for osteosynthesis and in sustained 
release forms of drugs, in:G.Gregoriadis 
(Ed.), Drug Carriers in Medicine, Academic 
Press, London. 1979; 237. 
21.  Singh M, Li XM, Wang HY, McGee JP, 
Zamb T, Koff W, Wang CY, O’Hagan DT. 
Immunogenecity and protection in small 
animal models with controlled release tetanus 
toxoid microparticles as a single-dose 
vaccine. Infect Immun 1997;65: 1716-1721. 
22. Illum L. Chitosan and its use as a 
pharmaceutical excipient. Pharm Res 1998; 
15:1326-1331. 
23. Felt O, Buri P, Gurny R. Chitosan: a unique 
polysaccharide for drug delivery. Drug Dev 
Ind Pharm 1998; 24:979-993. 
24. Joane RJ, Frier M, Perkins AC, Jones NS, 
Davis SS, Illum L. Evaluation of the 
clearance characteristics of bioadhesive 
48 
 
Saravana et al. International Journal of Drug Delivery 3 (2011) 43-50 
 
systems in humans. Int J Pharm 1999; 
178:55-65. 
25. Vander Lubben LM, Verhoef JC, Borchard G, 
Junginger HE. Chitosans for mucosal 
vaccination. Adv Drug Deliv Rev 
2001;52:139-144. 
26. Derek T, O’Hagan DT, Rino Rappuoli. Novel 
approaches to vaccine delivery. 
Pharmaceutical Research 2004; 21(9): 1519-
1530. 
27. Valiante NM, O’Hagan DT, Ulmer J. Innate 
immunity and biodefense vaccines. Cell 
Microbiol 2003; 5:755-760. 
28. Artursson P, Lindmark T, Davis SS, Illum L. 
Effect of chitosan on the permeability of 
monolayers of intestinal epithelial cells 
(Caco-2). Pharm Res 1994; 11:1358–1361. 
29. Borchard G, Luessen HL, De Boer AG, 
Verhoef JC, Lehr CM, Junginger HE. The 
poteltial of mucoadhesive polymers in 
enhancing intestinal peptide drus absorption. 
III: Effect of chitosan glutamate and 
carbomer on epithelial tight junctions in vitro. 
J Control Release 1996; 39:131–138. 
30. Dodane V, Khan MA, Merwin JR. Effect of 
chitosan on epithelial permeability and 
structure. Int J Pharm 1999; 182:21–32. 
31. Schipper NG, Varum KM, Artursson P. 
Chitosans as absorption enhancers for poorly 
absorbable drugs. 1: Influence of molecular 
weight and degree of acetylation on drug 
transport across human intestinal epithelial 
(Caco-2) cells. Pharm Res 1996; 13:1686–
1692. 
32. Luessen HL, de Leeuw BJ, Langemeyer MW, 
de Boer AB, Verhoef JC, Junginger HE. 
Mucoadhesive polymers in peroral peptide 
drug delivery. VI. Carbomer and chitosan 
improve the intestinal absorption of the 
peptide drug buserelin in vivo. Pharm Res 
1996; 13:1668–1672. 
33. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis 
SS, Illum L. Stimulation of mucosal and 
systemic antibody responses against 
Bordetella pertussis filamentous 
haemagglutinin and recombinant pertussis 
toxin after nasal administration with chitosan 
in mice. Vaccine 1998; 16:2039–2046. 
34. McNeela EA, O'Connor D, Jabbal-Gill I, 
Illum L, Davis SS, Pizza M, et al. A mucosal 
vaccine against diphtheria: formulation of 
cross reacting material (CRM (197)) of 
diphtheria toxin with chitosan enhances local 
and systemic antibody and Th2 responses 
following nasal delivery. Vaccine 2000; 
19:1188–1198. 
35. Xie Y, Zhou NJ, Gong YF, Zhou XJ, Chen J, 
Hu SJ, et al. Th immune response induced by 
H. pylori vaccine with chitosan as adjuvant 
and its relation to immune protection. World J 
Gastroenterol 2007; 13:1547–1553. 
36. Seferian PG, Martinez ML. Immune 
stimulating activity of two new chitosan 
containing adjuvant formulations. Vaccine 
2000; 19:661–668. 
37. Soane RJ, Hinchcliffe M, Davis SS, Illum L. 
Clearance characteristics of chitosan based 
formulations in the sheep nasal cavity. Int J 
Pharm 2001;217:183–191. 
38. Desai MP, Labhasetwar V, Walter E, Levy 
RJ, Amidon GL. The mechanism of uptake of 
biodegradable microparticles in Caco-2 cells 
is size dependent. Pharm Res 1997; 14:1568–
1573. 
39. Eldridge JH, Staas JK, Meulbroek JA, Tice 
TR, Gilley RM. Biodegradable and 
biocompatible poly(DL-lactide-co-glycolide) 
microspheres as an adjuvant for 
staphylococcal enterotoxin B toxoid which 
enhances the level of toxin-neutralizing 
antibodies. Infect Immun 1991; 59:2978–
2986. 
40. O'Hagan DT, Jeffery H, Davis SS. Long-term 
antibody responses in mice following 
subcutaneous immunization with ovalbumin 
entrapped in biodegradable microparticles. 
Vaccine 1993a; 11:965–969. 
41. Pereswetoff-Morath L. Microspheres as nasal 
drug delivery systems. Adv Drug Deliv Rev 
1998;29:185–194. 
42. Chowdary KP, Rao YS. Mucoadhesive 
microspheres for controlled drug delivery. 
Biol Pharm Bull 2004;27:1717–1724. 
49 
 
Saravana et al. International Journal of Drug Delivery 3 (2011) 43-50 
 
43. Tian J, Yu J, Sun X. Chitosan microspheres 
as candidate plasmid vaccine carrier for oral 
immunisation of Japanese flounder 
(Paralichthys olivaceus). Vet Immunol 
Immunopathol 2008; 126:220–229. 
 
44. Ahire VJ, Sawant KK, Doshi JB, Ravetkar 
SD. Chitosan microparticles as oral delivery 
system for tetanus toxoid. Drug Dev Ind 
Pharm 2007;33:1112–1124. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45. Takahiro Nagamoto, Yoshiyuki Hattori, Kozo 
Takayama, Yoshie Maitani. Novel chitosan 
particles and chitosan-coated emulsions 
inducing immune response via intranasal 
vaccine delivery. Pharmacological Research, 
21(4), 671-674 (2004).  
46. Arthanari Saravanakumar, Nachipalayam 
Muthusamy Ramaswamy. Formulation and 
in-vitro evaluation of tetanus toxoid loaded 
chitosan microspheres. J of Pharm Research 
2009; 2(5): 893-896.     
50 
 
